Harvard Bioscience Inc. (HBIO)
NASDAQ: HBIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $39.60M
- Forward P/E
- 16.34
- EPS (TTM)
- -$2.59
- Dividend yield
- None
- 52-week range
- 4.00 – 10.20
- Day range
- 8.53 – 9.00
- Volume / Avg
- 22.66K / 21.82K
- Beta
- —
- Shares outstanding
- 4.57M
52-week range
HBIO stock today
Harvard Bioscience (HBIO) closed at $8.66 on Nov 20, down 0.23% (-$0.02), versus the S&P 500's 3.70% decline. At this level, HBIO sits in the middle of its 52-week range of $4.00 to $10.20: 15.1% below the high, set on Nov 11, 2026 and 116.5% above the low. HBIO is up 29.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 37.5%.
Harvard Bioscience has posted a net loss over the last twelve months (EPS of -$2.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Harvard Bioscience
Company profileHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. John Duke
- Headquarters
- Holliston, MA
- Employees
- 316
- IPO year
- 2000
- Website
- harvardbioscience.com
Financial highlights
Full financialsIn fiscal 2025, Harvard Bioscience generated $86.5 million in revenue, down 8.1% from fiscal 2024, its first annual decline since 2024. Harvard Bioscience reported a net loss of $56.7 million, compared with a loss of $12.4 million a year earlier. Gross margin was 57.7% (down from 58.2%) and operating margin -56.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $86.55M | $94.14M | $112.25M | $113.33M | $118.90M |
| Growth | -8.06% | -16.14% | -0.96% | -4.68% | +16.46% |
| Net income | $-56.70M | $-12.40M | $-3.42M | $-9.52M | $-288.00K |
| EPS (diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$7.50-13.39%
- Strong buy 1
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.10 vs $-0.65
- Surprise
- +84.62%
HBIO news
All HBIO news- Harvard Bioscience Consensus Price Target Raised 26.83% to $13.26Nasdaq
- Harvard Bioscience (HBIO) Q3 2026 Earnings Call TranscriptNasdaq
- Harvard Bioscience Announces Third Quarter 2026 Financial ResultsGlobeNewswire
- Harvard Bioscience Consensus Price Target Increased by 36.67% to $10.46Nasdaq
- Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services ForumGlobeNewswire
- Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ETGlobeNewswire
Harvard Bioscience peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs HBIO |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs HBIO |
| EYPTEyePoint Inc. | 0.2342 | -11.36% | $26.65M | vs HBIO |
| CIRCCircle8 Group Inc. | 0.1361 | -12.25% | $15.99M | vs HBIO |
| BNGOBionano Genomics Inc. | 0.8222 | -7.11% | $11.50M | vs HBIO |
| ASTCAstrotech Corporation (DE) | 3.50 | -0.85% | $7.45M | vs HBIO |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs HBIO |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs HBIO |
Indexes, lists and sector
Harvard Bioscience stock FAQ
What is Harvard Bioscience's stock price today?
HBIO last traded at $8.66 as of Nov 20, 4:00 PM EST, down 0.23% on the day. Prices are delayed at least 15 minutes.
Does Harvard Bioscience pay a dividend?
No. Harvard Bioscience does not currently pay a regular cash dividend.
Who is Harvard Bioscience's CEO?
Mr. John Duke is the chief executive officer of Harvard Bioscience Inc., which has about 316 employees.
Has HBIO ever split its stock?
Yes. The most recent HBIO stock split was a 1-for-10 split on Mar 16, 2026, one of 2 splits on record.
What is the HBIO 52-week high?
The 52-week high for HBIO is $10.20 and the 52-week low is $4.00. The stock is currently 15.1% below its high.